Security record · archived quarter
HAE
Haemonetics Corporation · Healthcare · Medical - Devices
2Tracked holders
-1Δ holders
467.31KShares held
$49.40MReported value
+0New positions
−1Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | -1 | 467.31K | $49.40M | n/a | −1 |
| Q2 2026 | 106 | -6 | 39.46M | $2.63B | +3 | −9 |
| Q1 2026 | 115 | +1 | 38.93M | $1.98B | +9 | −9 |
| Q4 2025 | 115 | -1 | 49.79M | $3.32B | +2 | −2 |
| Q3 2025 | 19 | 0 | 21.92M | $1.07B | +1 | −2 |
| Q2 2025 | 17 | +1 | 20.74M | $1.55B | +1 | n/a |
| Q1 2025 | 13 | -1 | 9.03M | $573.92M | +1 | −2 |
| Q4 2024 | 14 | 0 | 9.30M | $726.05M | +1 | −1 |
| Q3 2024 | 13 | -3 | 7.86M | $631.67M | n/a | −3 |
| Q2 2024 | 16 | n/a | 7.65M | $633.10M | n/a | n/a |
Who holds it · Q3 2026
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assenagon Asset Management S.A. | 453.58K | +546.0% | $47.76M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 2 | Wealth Enhancement Advisory… | 13.73K | +18.5% | $1.64M | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| TD Waterhouse Canada Inc. | $23,512 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 321 holders, 47.04M shares, $2.56B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2026 ·
Methodology ·
Get this via the API